Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
ACXP Acurx Pharmaceuticals
3.500-0.010-0.28%
Close
02/03 16:00 ET
High
3.610
Open
3.570
Turnover
85.45K
Low
3.470
Pre Close
3.510
Volume
23.95K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Analysts Offer Insights on Healthcare Companies: Ocuphire Pharma (OCUP), Aridis Pharmaceuticals (ARDS) and Acurx Pharmaceuticals (ACXP)
Acurx Is Vying for Standard of Care in Treating Primary and Recurrent C. Diff
Acurx Pharmaceuticals to Present at the Emerging Growth Conference on January 25, 2023
Acurx invites individual and institutional investors, financial advisors and analysts to attend its real-time, interactive question and answer session at the Emerging Growth Conference STATEN ISLAND
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) Short Interest Up 26.8% in December
Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP – Get Rating) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling
Acurx Pharmaceuticals (NASDAQ:ACXP) Research Coverage Started at HC Wainwright
HC Wainwright assumed coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) in a research note published on Monday morning, The Fly reports. The firm issued a buy rating and a $14.00
Acurx Pharmaceuticals (NASDAQ:ACXP) Receives New Coverage From Analysts at HC Wainwright
HC Wainwright initiated coverage on shares of Acurx Pharmaceuticals (NASDAQ:ACXP – Get Rating) in a report released on Monday morning, The Fly reports. The firm issued a buy rating and a $14.00 price
Benzinga's Top Ratings Upgrades, Downgrades For December 19, 2022
UpgradesFor NRG Energy Inc (NYSE:NRG), B of A Securities upgraded the previous rating of Underperform to Neutral. For the third quarter, NRG Energy had an EPS of $0.29, compared to year-ago quarter EP
Acurx Pharmaceuticals Price Target Announced at $14.00/Share by HC Wainwright & Co.
Acurx Pharmaceuticals Price Target Announced at $14.00/Share by HC Wainwright & Co.
Acurx Pharmaceuticals Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 12/19/2022 265.54% HC Wainwright & Co. → $14 Initiates Coverage On → Buy 11/29/2021 213.32% Maxim Group →
HC Wainwright & Co. Initiates Coverage On Acurx Pharmaceuticals With Buy Rating, Announces Price Target of $14
HC Wainwright & Co. analyst Ed Arce initiates coverage on Acurx Pharmaceuticals (NASDAQ:ACXP) with a Buy rating and announces Price Target of $14.
Company Overview
More
Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. Its approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme. Its research and development pipeline includes early-stage antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus, Vancomycin-Resistant Enterococcus and Penicillin-Resistant Streptococcus pneumoniae. The company was founded by David P. Luci, Robert G. Shawah and Robert J. DeLuccia in July 2017 and is headquartered in New York, NY.
CEO： Mr. David P. Luci
Market： NASDAQ
Listing Date： 06/25/2021
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet